Filed by: Supernus Pharmaceuticals, Inc.
and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934
• Record total revenues of $226.8 million in the third quarter 2026, an 18% increase compared to same period last year.
• Combined revenues of the Company's four growth products increased to $192.2 million in the third quarter 2026, representing an increase of 29% compared to the same period last year. This strong growth was driven by an increase in net sales of Qelbree ® , GOCOVRI ® , ZURZUVAE ® , and ONAPGO™. • Received orphan-drug exclusive approval for ONAPGO and submitted an sNDA to the FDA to add a second supplier.
• Merger with Indivior Pharmaceuticals, Inc. (Indivior) expected to close on November 2, 2026.
– Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the third quarter 2026 and associated Company developments. “Our strong operating execution year-to-date delivered total revenue growth of 29%, which shows the continued momentum across our commercial portfolio, specifically our growth products.” said Jack Khattar, President and Chief Executive Officer of Supernus. “We look forward to closing the merger with Indivior next week, which will create a diverse CNS biopharmaceutical leader positioned to serve more patients and deliver long-term value for shareholders.”
• ONAPGO net product sales were $17.1 million in the third quarter of 2026. Demand for the product continued to be healthy, with more than 400 enrollment forms submitted in the third quarter. In the third quarter 2026, prescriptions grew by 17% compared to the second quarter 2026. The U.S. Food and Drug Administration (FDA) has recognized seven years of orphan-drug exclusive approval for ONAPGO for the treatment of motor fluctuations in adults with advanced Parkinson’s disease. In addition, the Company submitted a supplemental New Drug Application (sNDA) for a second supplier for ONAPGO, with potential FDA approval by mid-year 2027. • Collaboration revenue from ZURZUVAE was $41.7 million in the third quarter of 2026. Collaboration revenue represents 50% of the net revenues for ZURZUVAE recorded by Biogen Inc. Third quarter 2026 U.S sales of ZURZUVAE, as reported by Biogen Inc., increased approximately 53% compared to the same period in 2025. The total number of prescriptions for ZURZUVAE increased by 43% in the third quarter of 2026 compared to the same period last year. 1 • Net sales of Qelbree increased 12% to $90.8 million in the third quarter of 2026, compared to the same period in 2025, driven primarily by volume growth. Total IQVIA prescriptions (6) for Qelbree were 282,887 for the third quarter 2026, representing an increase of 18% compared to the same period last year. Prescription growth in the adult and pediatric populations was 25% and 16%, respectively, compared to the same period last year.
• GOCOVRI grew by approximately 4% in net sales and 4% in prescriptions in the third quarter of 2026, compared to the same period in 2025. Net sales reached an all-time high of $42.6 million in the third quarter of 2026.
• The Phase 2b randomized, double-blind, placebo-controlled study of 3mg and 4mg twice daily doses is ongoing with a targeted enrollment of approximately 258 adult patients with treatment resistant focal seizures. SPN-820 – Novel first-in-class molecule that increases mTORC1 mediated synaptic function for depression • The Phase 2b multi-center, randomized, double-blind, placebo-controlled trial in approximately 200 adults with major depressive disorder (MDD). The study will examine the safety and tolerability of SPN-820 2400mg given intermittently (twice weekly) as an adjunctive treatment to the current baseline antidepressant therapy, as well as assess the rapid onset of improvement in depressive symptoms.
SPN-443 – Novel stimulant for attention-deficit/hyperactivity disorder (ADHD) • The Company expects to initiate a Phase 1 single-ascending/multiple-ascending dose study in adult healthy volunteers by the end of 2026.
Strategic Merger with Indivior Pharmaceuticals, Inc On August 3, 2026, Supernus announced that it had entered into an agreement to combine in an all-stock merger with Indivior. The combination will create a diversified CNS biopharmaceutical leader with significant scale and financial resources to accelerate growth opportunities. The go-forward company, to be named Supernus, Inc., is expected to generate significant value for shareholders of both companies and expected to realize $125 million in annual cost synergies. The merger was approved by the shareholders of both companies on October 15, 2026, and is expected to close on November 2, 2026. Supernus, Inc. will be listed on the Nasdaq Global Market and will begin trading under the ticker symbol “SUPN” on November 3, 2026.
This section includes information on non-GAAP financial measures. See "Non-GAAP Financial Information" section for information on non-GAAP financial measures. In addition, a reconciliation of applicable GAAP to non-GAAP financial information is included at the end of this press release. 2
The following table provides information regarding total revenues (dollars in millions):
Total revenues from commercial products (non-GAAP) (1)(4) represent revenues from our product sales to customers and through our collaboration agreement with Biogen.
• Operating earnings (loss) was an earnings of $21.2 million and a loss of $45.1 million for three and nine months ended September 30, 2026, compared to an operating loss of $60.2 million and $58.3 million for the same period in 2025 . The increase in the three month period ended September 30, 2026 was primarily due to higher revenues, as well as a decrease in selling, general, and administrative expenses due to the absence of acquisition-related costs associated with the acquisition of Sage in the third quarter of 2025. The increase in the nine month period ended September 30, 2026 was primarily due to higher revenues.
• Adjusted operating earnings (non-GAAP) (1) were $55.2 million and $115.2 million for three and nine months ended September 30, 2026, compared to $41.9 million and $110.2 million for the same period in 2025.
• Net earnings (loss) and diluted earnings (loss) per share were $20.9 million and $0.35 for the three months and $(39.8) million and $(0.69) for nine months ended September 30, 2026, respectively, compared to net loss and diluted loss per share of $(45.1) million and $(0.80) for the three months and $(34.4) million and $(0.61) nine months ended September 30, 2025, respectively.
• Cash, cash equivalents, and current marketable securities were approximately $359.5 million as of September 30, 2026, compared to $308.7 million as of December 31, 2025. This increase was primarily due to cash generated from operations. 3
As a stand-alone company, the Company is raising its guidance for the full year 2026 financial guidance as set forth below (dollars in millions):
Assuming the merger is completed on November 2, 2026, we will operate as a combined company, and the guidance above will no longer apply.
This press release contains financial measures that present financial information which do not comply with United States generally accepted accounting principles (GAAP). The non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, or superior to measures prepared in accordance with GAAP. Non-GAAP adjusted operating earnings on a historical and projected basis adjusts for non-cash share-based compensation expense, depreciation and amortization, intangible asset impairment charges and changes to fair value of contingent consideration, and for factors that are unusual, non-recurring or unpredictable, and excludes those costs, expenses, and other specified items presented in the reconciliation tables in this press release. We also present total revenues excluding net sales of Trokendi XR (GAAP) and Oxtellar XR (GAAP), which is a non-GAAP measure and is calculated as total revenues (GAAP) less net product sales of Trokendi XR (GAAP) and Oxtellar XR (GAAP). Beginning in the year a product loses exclusivity due to generic entrants, we generally do not expect net product sales of such products to constitute a significant part of our revenue in the future. We also present total revenues from commercial products, which is also a non-GAAP measure and is calculated as the combined total of total net product sales (GAAP) and collaboration revenues (GAAP). We believe that the use of non-GAAP financial measures provides useful supplemental information to management, investors, analysts and others regarding the Company's revenue and results of operations and assist management, investors, analysts, and others in understanding and evaluating our revenue growth and the performance of the business.
There are limitations associated with the use of non-GAAP financial measures and therefore comparability may be limited. These limitations include: non-GAAP financial measures that may not be entirely comparable to similarly titled measures used by other companies; these may not reflect all items of income and expense, as applicable, that affect our operations; there may be potential differences among calculation methodologies; these may differ from the non-GAAP information used by other companies, including peer companies. We mitigate these limitations by reconciling the non-GAAP financial measure to the most comparable GAAP financial measure. Investors are encouraged to review the reconciliation. The Company's 2026 financial guidance is also being provided on both a GAAP and a non-GAAP basis.
(1) See the section titled "Non-GAAP Financial Information" for information about this non-GAAP financial measure. A reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure is included at the end of this press release.
(3) Represents proportionate share of collaboration revenue from Biogen’s sales of ZURZUVAE to customers in the U.S. from July 31, 2025, the closing of the acquisition of Sage Therapeutics, Inc.
(4) Total revenues from commercial products, a non-GAAP measure, represents revenues from our product sales to customers and through our collaboration agreement with Biogen.
(5) Royalty, licensing, and other revenues include royalties on generic Trokendi XR, Oxtellar XR, other licensed products and intellectual property.
(7) Includes net product sales, collaboration revenue, and royalty, licensing, and other revenue. 4
Supernus will host a conference call and webcast today, October 29, 2026, at 4:30 p.m. ET.to discuss its third quarter and nine months results. A live webcast will be available in the Events & Presentations section of the Company's Investor Relations website www.supernus.com/investors . Participants may also pre-register any time before the call here . Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.
Following the live call, a replay will be available on the Company's Investor Relations website www.supernus.com/investors. The webcast will be available on the Company's website for 60 days following the live call.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for attention- deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel product candidates for CNS disorders.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "may," "will," "would," "could," "should," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. These statements do not convey historical information but relate to predicted or potential future events that are based upon management’s current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the risk that the proposed merger may not be completed; the possibility that competing offers or acquisition proposals for Supernus or Indivior will be made; the delay or failure of the merger conditions to be satisfied (or waived), including the receipt of required approvals from stockholders of Supernus and Indivior; the failure (or delay) to receive the required regulatory approvals of the proposed merger; the possibility that prior to the completion of the transactions contemplated by the merger agreement, Supernus’s or Indivior’s business may experience significant disruptions due to transaction related uncertainty; the effects of disruption from the transactions on Supernus’s and Indivior’s business and the fact that the announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees, manufacturers, suppliers, vendors, business partners and distribution channels to patients; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the risk that Supernus may be required to pay a termination fee to Indivior in specified circumstances in which the merger agreement is terminated, and the possibility that the existence of such fee may discourage third parties from proposing an alternative transaction; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; the restrictions on the conduct of Supernus’s business during the pendency of the merger under the interim operating covenants contained in the merger agreement, which may limit Supernus’s ability to pursue business opportunities, make acquisitions or dispositions, incur indebtedness, make capital expenditures, or otherwise take actions it would have taken absent the merger agreement, or to respond to competitive pressures or developments in its industry; the diversion of the attention and resources of Supernus’s management and employees from ongoing business operations and opportunities as a result of the substantial time and effort required to complete the merger and to prepare for integration; the fact that the exchange ratio is fixed and will not be adjusted for changes in the market price of Supernus or Indivior common stock prior to the consummation of the merger, which may decrease the value of the consideration received by Supernus stockholders in connection with the merger; the risk that the anticipated benefits, synergies and cost savings of the merger may not be realized, or may not be realized within the expected timeframe; the difficulties, costs and unanticipated liabilities associated with integrating the businesses, operations, systems, product portfolios and personnel of Supernus and Indivior; the risk that the combined company may be unable to retain and motivate key employees during the pendency of the merger and following its consummation; Supernus’s ability to sustain and increase its profitability; Supernus’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of Supernus’s corporate strategy; Supernus’s future financial performance and projected expenditures; Supernus’s ability to increase the number of prescriptions written for each of its products, and the products of its subsidiaries; Supernus’s ability to increase its net revenue from its products, and the products of its subsidiaries; Supernus’s ability to commercialize its products, and the products of its subsidiaries; Supernus’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; Supernus’s product research and development activities, including the timing and progress of Supernus’s clinical trials, and projected expenditures; Supernus’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize Supernus’s product candidates; Supernus’s ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; Supernus’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of Supernus’s product candidates; the accuracy of Supernus’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; Supernus’s ability to increase its manufacturing capabilities for its products and product candidates; Supernus’s projected markets and growth in markets; Supernus’s product formulations and patient needs and potential funding sources; Supernus’s staffing needs; changes to laws and regulations applicable to the pharmaceuticals industry; the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs; and other risk factors set forth from time to time in Supernus’s and Indivior’s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. Supernus undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events. 6
September 30, Assets 2026 December 31, Current assets (unaudited) 2025 ────────────────────────────────────────────────────────────────────────────── Cash and cash $ 175,884 $ 128,448 equivalents Marketable securities 183,575 180,222 Accounts receivable, 214,714 187,802 net Inventories, net 87,112 82,385 Prepaid expenses and other current 49,930 65,325 assets Total current assets 711,215 644,182 Restricted cash 1,450 1,450 Property and 10,021 10,531 equipment, net Intangible assets, 446,238 569,456 net Goodwill 119,431 124,882 Deferred income tax 54,317 38,351 assets, net Other assets 55,018 63,796 Total assets $ 1,397,690 $ 1,452,648 Liabilities and stockholders' equity Current liabilities Accounts payable and $ 109,136 $ 107,800 accrued liabilities Accrued product 165,348 161,097 returns and rebates Contingent consideration, — 31,052 current portion Other current 10,913 38,222 liabilities Total current 285,397 338,171 liabilities Contingent consideration, 206 206 long-term Operating lease liabilities, 28,577 30,365 long-term Other liabilities 21,032 22,192 Total liabilities 335,212 390,934 Stockholders' equity Common stock, $0.001 par value; 130,000,000 shares authorized; 58,254,131 and 57,457,462 shares 58 57 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively Additional paid-in 584,575 543,825 capital Accumulated other comprehensive loss, -280 -44 net of tax Retained earnings 478,125 517,876 Total stockholders' 1,062,478 1,061,714 equity Total liabilities and stockholders' $ 1,397,690 $ 1,452,648 equity
(unaudited) Reconciliation of GAAP Total revenues to Non-GAAP Total revenues excluding Trokendi XR and Oxtellar XR net sales
An itemized reconciliation between total revenues on a GAAP basis and total revenues excluding Trokendi XR and Oxtellar XR net sales, a non-GAAP measure, is as follows (dollars in millions):
___________________________________________ (a) Includes net product sales, collaboration revenue, and royalty, licensing, and other revenues. Reconciliation of GAAP Net Product Sales to Non-GAAP Revenues from Commercial Products
An itemized reconciliation between Net product sales on a GAAP basis and total revenues from commercial products, a non-GAAP measure, is as follows (dollars in millions):
Total revenues from commercial products, a non-GAAP measure, represents revenues from our product sales to customers and through our collaboration agreement with Biogen. 9 Reconciliation of GAAP Operating Earnings (Loss) to Non-GAAP Adjusted Operating Earnings
An itemized reconciliation between operating earnings (loss) on a GAAP basis and adjusted operating earnings on a non-GAAP basis is as follows (dollars in millions):
Non-GAAP adjusted operating earnings adjusts for non-cash items, which include amortization of intangible assets, share-based compensation expense, change in fair value of contingent consideration, depreciation, and intangible asset impairment charges.
Reconciliation of Full Year 2026 Financial Guidance - GAAP Operating Earnings (Loss) to Non-GAAP Adjusted Operating Earnings
An itemized reconciliation between projected operating earnings (loss) on a GAAP basis for the full year 2026 and projected adjusted operating earnings on a non- GAAP basis for the full year 2026 is as follows (dollars in millions):
Current Guidance (as of October 29, Prior Guidance 2026) (as of August 4, 2026) ────────────────────────────────────────────────────────────────────────────── Operating earnings $(5) - $(40) $(20) - $(50) (loss) - GAAP Adjustments: Amortization of $97 $97 intangible assets Intangible asset $55 $55 impairment charges Share-based $35 $35 compensation Contingent $2 $2 consideration loss Depreciation $3 $3 Operating earnings - As Adjusted $160 - $180 $150 - $180 (non-GAAP)
Full text with the tables
Filed by: Supernus Pharmaceuticals, Inc.
Pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of
1934
Subject Company: Supernus Pharmaceuticals, Inc.
Commission File No.: 001-35518
Date: October 29, 2026
Exhibit 99.1
Supernus Announces Third Quarter 2026 Financial Results
• Record total revenues of $226.8 million in the third quarter 2026, an 18%
increase compared to same period last year.
• Combined revenues of the Company's four growth products increased to $192.2
million in the third quarter 2026, representing an increase of 29% compared to
the same period last year. This strong growth was driven by an increase in net
sales of Qelbree ® , GOCOVRI ® , ZURZUVAE ® , and ONAPGO™.
• Received orphan-drug exclusive approval for ONAPGO and submitted an sNDA to
the FDA to add a second supplier.
• Merger with Indivior Pharmaceuticals, Inc. (Indivior) expected to close on
November 2, 2026.
ROCKVILLE, Md., October 29, 2026
– Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company
focused on developing and commercializing products for the treatment of central
nervous system (CNS) diseases, today announced financial results for the third
quarter 2026 and associated Company developments.
“Our strong operating execution year-to-date delivered total revenue growth of
29%, which shows the continued momentum across our commercial portfolio,
specifically our growth products.” said Jack Khattar, President and Chief
Executive Officer of Supernus. “We look forward to closing the merger with
Indivior next week, which will create a diverse CNS biopharmaceutical leader
positioned to serve more patients and deliver long-term value for shareholders.”
Commercial Highlights
• ONAPGO net product sales were $17.1 million in the third quarter of 2026.
Demand for the product continued to be healthy, with more than 400 enrollment
forms submitted in the third quarter. In the third quarter 2026, prescriptions
grew by 17% compared to the second quarter 2026. The U.S. Food and Drug
Administration (FDA) has recognized seven years of orphan-drug exclusive
approval for ONAPGO for the treatment of motor fluctuations in adults with
advanced Parkinson’s disease. In addition, the Company submitted a supplemental
New Drug Application (sNDA) for a second supplier for ONAPGO, with potential FDA
approval by mid-year 2027.
• Collaboration revenue from ZURZUVAE was $41.7 million in the third quarter of
2026. Collaboration revenue represents 50% of the net revenues for ZURZUVAE
recorded by Biogen Inc. Third quarter 2026 U.S sales of ZURZUVAE, as reported by
Biogen Inc., increased approximately 53% compared to the same period in 2025.
The total number of prescriptions for ZURZUVAE increased by 43% in the third
quarter of 2026 compared to the same period last year.
1
• Net sales of Qelbree increased 12% to $90.8 million in the third quarter of
2026, compared to the same period in 2025, driven primarily by volume growth.
Total IQVIA prescriptions (6) for Qelbree were 282,887 for the third quarter
2026, representing an increase of 18% compared to the same period last year.
Prescription growth in the adult and pediatric populations was 25% and 16%,
respectively, compared to the same period last year.
• GOCOVRI grew by approximately 4% in net sales and 4% in prescriptions in the
third quarter of 2026, compared to the same period in 2025. Net sales reached an
all-time high of $42.6 million in the third quarter of 2026.
Product Pipeline Update
SPN-817 – Novel first-in-class highly selective AChE inhibitor for epilepsy
• The Phase 2b randomized, double-blind, placebo-controlled study of 3mg and 4mg
twice daily doses is ongoing with a targeted enrollment of approximately 258
adult patients with treatment resistant focal seizures.
SPN-820 – Novel first-in-class molecule that increases mTORC1 mediated synaptic
function for depression
• The Phase 2b multi-center, randomized, double-blind, placebo-controlled trial
in approximately 200 adults with major depressive disorder (MDD). The study will
examine the safety and tolerability of SPN-820 2400mg given intermittently
(twice weekly) as an adjunctive treatment to the current baseline antidepressant
therapy, as well as assess the rapid onset of improvement in depressive
symptoms.
SPN-443 – Novel stimulant for attention-deficit/hyperactivity disorder (ADHD)
• The Company expects to initiate a Phase 1 single-ascending/multiple-ascending
dose study in adult healthy volunteers by the end of 2026.
Strategic Merger with Indivior Pharmaceuticals, Inc
On August 3, 2026, Supernus announced that it had entered into an agreement to
combine in an all-stock merger with Indivior. The combination will create a
diversified CNS biopharmaceutical leader with significant scale and financial
resources to accelerate growth opportunities. The go-forward company, to be
named Supernus, Inc., is expected to generate significant value for shareholders
of both companies and expected to realize $125 million in annual cost synergies.
The merger was approved by the shareholders of both companies on October 15,
2026, and is expected to close on November 2, 2026. Supernus, Inc. will be
listed on the Nasdaq Global Market and will begin trading under the ticker
symbol “SUPN” on November 3, 2026.
Financial Highlights
This section includes information on non-GAAP financial measures. See "Non-GAAP
Financial Information" section for information on non-GAAP financial measures.
In addition, a reconciliation of applicable GAAP to non-GAAP financial
information is included at the end of this press release.
2
Revenues
The following table provides information regarding total revenues (dollars in
millions):
Thr… Nine
Mon… Mon…
End… End…
Sep… Sep…
Net 30, 30,
pr… 2026 Cha… 2026 Cha…
sa… (un… 2025 % (un… 2025 %
──────────────────────────────────────────────────────────────────────────────
Qe… $ 90.8 $ 81.4 12% $ 257… $ 223.7 15%
GO… 42.6 40.8 4% 115… 108.2 7%
ON… 17.1 6.8 151% 39.0 8.4 364%
Tr… 10.2 10.0 2% 28.1 34.0 (17…
XR®
Ox… 8.0 12.1 (34… 24.2 33.9 (29…
XR®
AP… 6.5 10.4 (38… 20.5 38.2 (46…
Ot… 3.4 7.0 (52… 9.9 22.1 (55…
To…
net 178… 168… 6% 495… 468.5 6%
pr…
sa…
Co…
re… 41.7 20.2 107% 104… 20.2 419%
(Z…
To…
re…
fr…
co… 220… 188… 17% 599… 488.7 23%
pr…
(N…
(4)
Ro…
li…
and 6.5 3.4 91% 53.8 18.7 188%
ot…
re…
To… $ 226… $ 192… 18% $ 653… $ 507.4 29%
re…
Total revenues from commercial products (non-GAAP) (1)(4) represent revenues
from our product sales to customers and through our collaboration agreement with
Biogen.
Other Financial Highlights
• Operating earnings (loss) was an earnings of $21.2 million and a loss of $45.1
million for three and nine months ended September 30, 2026, compared to an
operating loss of $60.2 million and $58.3 million for the same period in 2025 .
The increase in the three month period ended September 30, 2026 was primarily
due to higher revenues, as well as a decrease in selling, general, and
administrative expenses due to the absence of acquisition-related costs
associated with the acquisition of Sage in the third quarter of 2025. The
increase in the nine month period ended September 30, 2026 was primarily due to
higher revenues.
• Adjusted operating earnings (non-GAAP) (1) were $55.2 million and $115.2
million for three and nine months ended September 30, 2026, compared to $41.9
million and $110.2 million for the same period in 2025.
• Net earnings (loss) and diluted earnings (loss) per share were $20.9 million
and $0.35 for the three months and $(39.8) million and $(0.69) for nine months
ended September 30, 2026, respectively, compared to net loss and diluted loss
per share of $(45.1) million and $(0.80) for the three months and $(34.4)
million and $(0.61) nine months ended September 30, 2025, respectively.
• Cash, cash equivalents, and current marketable securities were approximately
$359.5 million as of September 30, 2026, compared to $308.7 million as of
December 31, 2025. This increase was primarily due to cash generated from
operations.
3
Full Year 2026 Financial Guidance
As a stand-alone company, the Company is raising its guidance for the full year
2026 financial guidance as set forth below (dollars in millions):
Current Guidance (as of Previous Guidance (as
October of August
29, 2026) 4, 2026)
──────────────────────────────────────────────────────────────────────────────
Total revenues include
the following(7):
◦ONAPGO net sales of
$60 million - $65
million $875 - $900 $860 - $890
◦Trokendi XR and
Oxtellar XR net sales
of $60 million - $67
million
Operating Earnings $(5) - $(40) $(20) - $(50)
(Loss) - GAAP
Operating Earnings -
As Adjusted $160 - $180 $150 - $180
(Non-GAAP)
Assuming the merger is completed on November 2, 2026, we will operate as a
combined company, and the guidance above will no longer apply.
Non-GAAP Financial Information
This press release contains financial measures that present financial
information which do not comply with United States generally accepted accounting
principles (GAAP). The non-GAAP financial measures should be considered in
addition to, not as a substitute for or in isolation from, or superior to
measures prepared in accordance with GAAP. Non-GAAP adjusted operating earnings
on a historical and projected basis adjusts for non-cash share-based
compensation expense, depreciation and amortization, intangible asset impairment
charges and changes to fair value of contingent consideration, and for factors
that are unusual, non-recurring or unpredictable, and excludes those costs,
expenses, and other specified items presented in the reconciliation tables in
this press release. We also present total revenues excluding net sales of
Trokendi XR (GAAP) and Oxtellar XR (GAAP), which is a non-GAAP measure and is
calculated as total revenues (GAAP) less net product sales of Trokendi XR (GAAP)
and Oxtellar XR (GAAP). Beginning in the year a product loses exclusivity due to
generic entrants, we generally do not expect net product sales of such products
to constitute a significant part of our revenue in the future. We also present
total revenues from commercial products, which is also a non-GAAP measure and is
calculated as the combined total of total net product sales (GAAP) and
collaboration revenues (GAAP). We believe that the use of non-GAAP financial
measures provides useful supplemental information to management, investors,
analysts and others regarding the Company's revenue and results of operations
and assist management, investors, analysts, and others in understanding and
evaluating our revenue growth and the performance of the business.
There are limitations associated with the use of non-GAAP financial measures and
therefore comparability may be limited. These limitations include: non-GAAP
financial measures that may not be entirely comparable to similarly titled
measures used by other companies; these may not reflect all items of income and
expense, as applicable, that affect our operations; there may be potential
differences among calculation methodologies; these may differ from the non-GAAP
information used by other companies, including peer companies. We mitigate these
limitations by reconciling the non-GAAP financial measure to the most comparable
GAAP financial measure. Investors are encouraged to review the reconciliation.
The Company's 2026 financial guidance is also being provided on both a GAAP and
a non-GAAP basis.
End Notes
(1) See the section titled "Non-GAAP Financial Information" for information
about this non-GAAP financial measure. A reconciliation of each non-GAAP
financial measure to the most directly comparable GAAP financial measure is
included at the end of this press release.
(2) Includes net product sales of MYOBLOC ® , XADAGO ® and Osmolex ER ® .
(3) Represents proportionate share of collaboration revenue from Biogen’s sales
of ZURZUVAE to customers in the U.S. from July 31, 2025, the closing of the
acquisition of Sage Therapeutics, Inc.
(4) Total revenues from commercial products, a non-GAAP measure, represents
revenues from our product sales to customers and through our collaboration
agreement with Biogen.
(5) Royalty, licensing, and other revenues include royalties on generic Trokendi
XR, Oxtellar XR, other licensed products and intellectual property.
(6) IQVIA data restatement July 1, 2025.
(7) Includes net product sales, collaboration revenue, and royalty, licensing,
and other revenue.
4
Conference Call Details
Supernus will host a conference call and webcast today, October 29, 2026, at
4:30 p.m. ET.to discuss its third quarter and nine months results. A live
webcast will be available in the Events & Presentations section of the Company's
Investor Relations website www.supernus.com/investors .
Participants may also pre-register any time before the call here . Once
registration is completed, participants will be provided a dial-in number with a
personalized conference code to access the call. Please dial in 15 minutes prior
to the start time.
Following the live call, a replay will be available on the Company's Investor
Relations website www.supernus.com/investors. The webcast will be available on
the Company's website for 60 days following the live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing
and commercializing products for the treatment of central nervous system (CNS)
diseases.
Our diverse neuroscience portfolio includes approved treatments for attention-
deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD)
patients receiving levodopa-based therapy, hypomobility in PD, postpartum
depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
We are developing a broad range of novel product candidates for CNS disorders.
For more information, please visit www.supernus.com .
5
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Words such as "anticipate,"
"believe," "estimate," "expect," "intend," "plan," "project," "may," "will,"
"would," "could," "should," and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements contain
these words. These statements do not convey historical information but relate to
predicted or potential future events that are based upon management’s current
expectations. These statements are subject to risks and uncertainties that could
cause actual results to differ materially from those expressed or implied by
such statements. In addition to the factors mentioned in this press release,
such risks and uncertainties include, but are not limited to, the risk that the
proposed merger may not be completed; the possibility that competing offers or
acquisition proposals for Supernus or Indivior will be made; the delay or
failure of the merger conditions to be satisfied (or waived), including the
receipt of required approvals from stockholders of Supernus and Indivior; the
failure (or delay) to receive the required regulatory approvals of the proposed
merger; the possibility that prior to the completion of the transactions
contemplated by the merger agreement, Supernus’s or Indivior’s business may
experience significant disruptions due to transaction related uncertainty; the
effects of disruption from the transactions on Supernus’s and Indivior’s
business and the fact that the announcement and pendency of the transactions may
make it more difficult to establish or maintain relationships with employees,
manufacturers, suppliers, vendors, business partners and distribution channels
to patients; the occurrence of any event, change or other circumstance that
could give rise to the termination of the merger agreement; the risk that
Supernus may be required to pay a termination fee to Indivior in specified
circumstances in which the merger agreement is terminated, and the possibility
that the existence of such fee may discourage third parties from proposing an
alternative transaction; the risk that stockholder litigation in connection with
the proposed transaction may result in significant costs of defense,
indemnification and liability; the restrictions on the conduct of Supernus’s
business during the pendency of the merger under the interim operating covenants
contained in the merger agreement, which may limit Supernus’s ability to pursue
business opportunities, make acquisitions or dispositions, incur indebtedness,
make capital expenditures, or otherwise take actions it would have taken absent
the merger agreement, or to respond to competitive pressures or developments in
its industry; the diversion of the attention and resources of Supernus’s
management and employees from ongoing business operations and opportunities as a
result of the substantial time and effort required to complete the merger and to
prepare for integration; the fact that the exchange ratio is fixed and will not
be adjusted for changes in the market price of Supernus or Indivior common stock
prior to the consummation of the merger, which may decrease the value of the
consideration received by Supernus stockholders in connection with the merger;
the risk that the anticipated benefits, synergies and cost savings of the merger
may not be realized, or may not be realized within the expected timeframe; the
difficulties, costs and unanticipated liabilities associated with integrating
the businesses, operations, systems, product portfolios and personnel of
Supernus and Indivior; the risk that the combined company may be unable to
retain and motivate key employees during the pendency of the merger and
following its consummation; Supernus’s ability to sustain and increase its
profitability; Supernus’s ability to raise sufficient capital to fully implement
its corporate strategy; the implementation of Supernus’s corporate strategy;
Supernus’s future financial performance and projected expenditures; Supernus’s
ability to increase the number of prescriptions written for each of its
products, and the products of its subsidiaries; Supernus’s ability to increase
its net revenue from its products, and the products of its subsidiaries;
Supernus’s ability to commercialize its products, and the products of its
subsidiaries; Supernus’s ability to enter into future collaborations with
pharmaceutical companies and academic institutions or to obtain funding from
government agencies; Supernus’s product research and development activities,
including the timing and progress of Supernus’s clinical trials, and projected
expenditures; Supernus’s ability to receive, and the timing of any receipt of,
regulatory approvals to develop and commercialize Supernus’s product candidates;
Supernus’s ability to protect its intellectual property and the intellectual
property of its subsidiaries and operate its business without infringing upon
the intellectual property rights of others; Supernus’s expectations regarding
federal, state and foreign regulatory requirements; the therapeutic benefits,
effectiveness and safety of Supernus’s product candidates; the accuracy of
Supernus’s estimates of the size and characteristics of the markets that may be
addressed by its product candidates; Supernus’s ability to increase its
manufacturing capabilities for its products and product candidates; Supernus’s
projected markets and growth in markets; Supernus’s product formulations and
patient needs and potential funding sources; Supernus’s staffing needs; changes
to laws and regulations applicable to the pharmaceuticals industry; the impact
of macroeconomic factors, such as economic downturns or uncertainty,
international conflict, trade disputes and tariffs; and other risk factors set
forth from time to time in Supernus’s and Indivior’s filings with the Securities
and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934, as amended. Supernus undertakes no obligation to update
the information in this press release to reflect events or circumstances after
the date hereof or to reflect the occurrence of anticipated or unanticipated
events.
6
Supernus Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
September 30,
Assets 2026 December 31,
Current assets (unaudited) 2025
──────────────────────────────────────────────────────────────────────────────
Cash and cash $ 175,884 $ 128,448
equivalents
Marketable securities 183,575 180,222
Accounts receivable, 214,714 187,802
net
Inventories, net 87,112 82,385
Prepaid expenses and
other current 49,930 65,325
assets
Total current assets 711,215 644,182
Restricted cash 1,450 1,450
Property and 10,021 10,531
equipment, net
Intangible assets, 446,238 569,456
net
Goodwill 119,431 124,882
Deferred income tax 54,317 38,351
assets, net
Other assets 55,018 63,796
Total assets $ 1,397,690 $ 1,452,648
Liabilities and
stockholders' equity
Current liabilities
Accounts payable and $ 109,136 $ 107,800
accrued liabilities
Accrued product 165,348 161,097
returns and rebates
Contingent
consideration, — 31,052
current
portion
Other current 10,913 38,222
liabilities
Total current 285,397 338,171
liabilities
Contingent
consideration, 206 206
long-term
Operating lease
liabilities, 28,577 30,365
long-term
Other liabilities 21,032 22,192
Total liabilities 335,212 390,934
Stockholders' equity
Common stock, $0.001
par value;
130,000,000 shares
authorized;
58,254,131 and
57,457,462 shares 58 57
issued
and outstanding as of
September 30, 2026
and December 31,
2025, respectively
Additional paid-in 584,575 543,825
capital
Accumulated other
comprehensive loss, -280 -44
net of tax
Retained earnings 478,125 517,876
Total stockholders' 1,062,478 1,061,714
equity
Total liabilities and
stockholders' $ 1,397,690 $ 1,452,648
equity
7
Supernus Pharmaceuticals, Inc.
Condensed Consolidated Statements of Loss
(in thousands, except share and per share data)
Three Nine
Months Months
Ended Ended
Septe… Septem…
30, 30,
2026 2026
Reve… (unau… 2025 (unaud… 2025
──────────────────────────────────────────────────────────────────────────────
Net
prod… $ 178,576 $ 168,5… $ 495,0… $ 468,525
sales
Coll…
reve… 41,697 20,164 104,6… 20,164
(ZUR…
Roya…
lice…
and 6,498 3,397 53,802 18,691
other
reve…
Total 226,771 192,1… 653,5… 507,380
reve…
Costs
and
expe…
Cost
of 27,018 18,965 84,078 51,555
reve…
Rese…
and 25,756 29,366 94,657 78,408
deve…
Sell…
gene… 128,056 179,6… 386,8… 363,173
and
admi…
Amor…
of 23,221 24,325 74,198 64,930
inta…
asse…
Impa… 1,541 — 56,460 —
char…
Cont…
cons… — — 2,391 7,660
loss
Total
costs 205,592 252,3… 698,6… 565,726
and
expe…
Oper…
earn… 21,179 -60,2… -45,1… -58,346
(los…
Other
inco…
(exp…
Inte…
and
other 2,248 2,277 7,260 11,230
inco…
net
Inte… -718 — -3,033 —
expe…
Total
other 1,530 2,277 4,227 11,230
inco…
net
Earn…
(los…
befo… 22,709 -57,9… -40,8… -47,116
inco…
taxes
Inco…
tax 1,796 -12,8… -1,138 -12,671
expe…
(ben…
Net
earn… $ 20,913 $ -45,1… $ -39,7… $ -34,445
(los…
Earn…
(los…
per
share
Basic $ 0.36 $ -0.80 $ -0.69 $ -0.61
Dilu… $ 0.35 $ -0.80 $ -0.69 $ -0.61
Weig…
aver…
shar…
outs…
Basic 58,202… 56,55… 57,97… 56,133…
Dilu… 59,471… 56,55… 57,97… 56,133…
(a) Excludes amortization of intangible assets.
8
Supernus Pharmaceuticals, Inc.
Reconciliations of GAAP to Non-GAAP Financial Information
(unaudited)
Reconciliation of GAAP Total revenues to Non-GAAP Total revenues excluding
Trokendi XR and Oxtellar XR net sales
An itemized reconciliation between total revenues on a GAAP basis and total
revenues excluding Trokendi XR and Oxtellar XR net sales, a non-GAAP measure, is
as follows (dollars in millions):
Thr… Nine
Mon… Mon…
End… End…
Sep… Cha… Sep… Cha…
2026 30, 2025 % 2026 30, 2025 %
──────────────────────────────────────────────────────────────────────────────
To…
re… $ 226… $ 192… 18% $ 653… $ 507.4 29%
(G…
Ad…
Tr…
XR
net -10… -10… 2% -28… -34.0 (17…
pr…
sa…
Ox…
XR
net -8.0 -12… (34… -24… -33.9 (29…
pr…
sa…
To…
re…
ex…
Tr…
XR
and $ 208… $ 170… 23% $ 601… $ 439.5 37%
Ox…
XR
net
sa…
(n…
___________________________________________
(a) Includes net product sales, collaboration revenue, and royalty, licensing,
and other revenues.
Reconciliation of GAAP Net Product Sales to Non-GAAP Revenues from Commercial
Products
An itemized reconciliation between Net product sales on a GAAP basis and total
revenues from commercial products, a non-GAAP measure, is as follows (dollars in
millions):
Thr… Nine
Mon… Mon…
End… End…
Sep… Cha… Sep… Cha…
2026 30, 2025 % 2026 30, 2025 %
──────────────────────────────────────────────────────────────────────────────
Net
pr… $ 178… $ 168… 6% $ 495… $ 468.5 6%
sa…
(G…
Ad…
Co…
re… 41.7 20.2 106% 104… 20.2 418%
(Z…
To…
re…
fr… $ 220… $ 188… 17% $ 599… $ 488.7 23%
co…
pr…
Total revenues from commercial products, a non-GAAP measure, represents revenues
from our product sales to customers and through our collaboration agreement with
Biogen.
9
Reconciliation of GAAP Operating Earnings (Loss) to Non-GAAP Adjusted Operating
Earnings
An itemized reconciliation between operating earnings (loss) on a GAAP basis and
adjusted operating earnings on a non-GAAP basis is as follows (dollars in
millions):
Three Nine
Months Months
Ended Ended
September September
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Operati…
earnings
(loss) - $ 21.2 $ -60.2 $ -45.1 $ -58.3
As
Reported
(GAAP)
Adjustm…
Amortiz…
of 23.2 24.3 74.2 64.9
intangi…
assets
Impairm… 1.5 — 56.4 —
charges
Share-b… 8.9 30.7 26.0 46.3
compens…
Conting…
conside… — — 2.4 7.7
loss
(gain)
Depreci… 0.4 0.5 1.3 1.6
Other
acquisi… — 46.6 — 48.0
costs
Operati…
earnings
- As $ 55.2 $ 41.9 $ 115.2 $ 110.2
Adjusted
(non-GA…
_________________________________________
Non-GAAP adjusted operating earnings adjusts for non-cash items, which include
amortization of intangible assets, share-based compensation expense, change in
fair value of contingent consideration, depreciation, and intangible asset
impairment charges.
Reconciliation of Full Year 2026 Financial Guidance - GAAP Operating Earnings
(Loss) to Non-GAAP Adjusted Operating Earnings
An itemized reconciliation between projected operating earnings (loss) on a GAAP
basis for the full year 2026 and projected adjusted operating earnings on a non-
GAAP basis for the full year 2026 is as follows (dollars in millions):
Current Guidance
(as of October 29, Prior Guidance
2026) (as of August 4, 2026)
──────────────────────────────────────────────────────────────────────────────
Operating earnings $(5) - $(40) $(20) - $(50)
(loss) - GAAP
Adjustments:
Amortization of $97 $97
intangible assets
Intangible asset $55 $55
impairment charges
Share-based $35 $35
compensation
Contingent $2 $2
consideration loss
Depreciation $3 $3
Operating earnings - As
Adjusted $160 - $180 $150 - $180
(non-GAAP)
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
ICR Healthcare
(443) 213-0505
[email protected]
10
11